Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solutions for APD: special considerations.

J Passlick-Deetjen1, T P Schaub, H Schilling

  • 1Fresenius Medical Care, Bad Homburg, Germany. Jutta.Passlick-Deetjen@fmc-ag.com

Seminars in Dialysis
|November 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Juvenile idiopathic epiretinal membrane].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2015
Same author

[Surgical treatment of neovascular glaucoma].

Klinische Monatsblatter fur Augenheilkunde·2014
Same author

Reduced complications during hemodialysis by automatic blood volume controlled ultrafiltration.

The International journal of artificial organs·2007
Same author

Effects of an increase in time vs. frequency on cardiovascular parameters in chronic hemodialysis patients.

Clinical nephrology·2006
Same author

[Endoresection of large uveal melanomas after pretreatment by single-dose stereotactic convergence irradiation with the leksell gamma knife--first experience on 46 cases].

Klinische Monatsblatter fur Augenheilkunde·2006
Same author

Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina.

The British journal of ophthalmology·2006
Same journal

Intracardiac Vascular Access for Hemodialysis Despite Associated Ascending Aortic Aneurysm.

Seminars in dialysis·2026
Same journal

Measures of Equivalent Hemodialysis Urea Clearance and Their Proposed Utility for Monitoring Adequacy.

Seminars in dialysis·2026
Same journal

Risk of Serious Adverse Events and Death With Low-Dose Methotrexate Versus Hydroxychloroquine in Adults Receiving Dialysis.

Seminars in dialysis·2026
Same journal

Severe Hematoma Following Initial Arteriovenous Fistula Puncture in a Hemodialysis Patient, Emphasizing Thoracic Outlet Syndrome: A Case Report.

Seminars in dialysis·2026
Same journal

Phosphate Kinetic Modeling in Patients Treated With Hemodialysis or Hemodiafiltration: A Prospective, Multicenter, Cross-Sectional Study.

Seminars in dialysis·2026
Same journal

Impact of Expanded Hemodialysis on Inflammation and Iron Metabolism in Chronic Hemodialysis Patients.

Seminars in dialysis·2026
See all related articles

Automated peritoneal dialysis (APD) offers advantages over traditional methods. New, biocompatible dialysis fluids show promise in preserving peritoneal membrane health during long-term APD treatment.

Area of Science:

  • Nephrology
  • Biomaterials Science
  • Medical Technology

Background:

  • Automated peritoneal dialysis (APD) is rapidly expanding in Europe and the US.
  • Standard peritoneal dialysis (PD) fluids may negatively impact the peritoneal membrane over time, especially with high-volume APD.
  • Existing research on PD fluids has primarily focused on continuous ambulatory PD (CAPD) patients.

Purpose of the Study:

  • To evaluate the impact of new, biocompatible PD fluids on peritoneal membrane preservation in APD patients.
  • To assess the benefits of pH-neutral PD solutions with low glucose degradation products (GDPs).
  • To explore optimal fluid compositions for APD, considering factors like sodium and calcium concentrations.

Main Methods:

  • In vitro, ex vivo, and in vivo studies were conducted using new PD fluid formulations.

Related Experiment Videos

  • Analysis included peritoneal cell viability, secretory functions, and advanced glycation end product (AGE) formation.
  • Effluent CA125 levels were monitored as an indicator of mesothelial cell preservation.

    • Main Results:

    • New PD fluids demonstrated improved peritoneal cell viability and function.
    • A significant reduction in AGE formation was observed with the new fluids.
    • Increased effluent CA125 levels suggest better preservation of peritoneal mesothelial cells.

    Conclusions:

    • New pH-neutral PD solutions with minimized GDPs represent a significant advancement for preserving the peritoneal membrane in long-term APD.
    • While new fluids enhance preservation, uremia and PD treatment itself can still cause membrane changes.
    • Individualized APD prescriptions, considering factors like sodium and calcium concentrations, are crucial for long-term treatment success.